Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
Open accessThe DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index.
Abstract
To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have antidepressive, anxiolytic, and antiaddictive properties. Thus, we conducted a systematic review of clinical trials published from 1990 until 2015, assessing these therapeutic properties. Electronic searches were performed using the PubMed, LILACS, and SciELO databases. Only clinical trials published in peer-reviewed journals were included. Of these, 151 studies were identified, of which six met the established criteria. Reviewed studies suggest beneficial effects for treatment-resistant depression, anxiety and depression associated with life-threatening diseases, and tobacco and alcohol dependence. All drugs were well tolerated. In conclusion, ayahuasca, psilocybin and LSD may be useful pharmacological tools for the treatment of drug dependence, and anxiety and mood disorders, especially in treatment-resistant patients. These drugs may also be useful pharmacological tools to understand psychiatric disorders and to develop new therapeutic agents. However, all studies reviewed had small sample sizes, and half of them were open-label, proof-of-concept studies. Randomized, double-blind, placebo-controlled studies with more patients are needed to replicate these preliminary findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“these medicines have demonstrated efficacy across a range of neuropsychiatric disorders including depression, PTSD, and addiction (156, 168–172)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“Most of these studies however suffer from low methodological validity and are mostly open-label, yet they have yielded preliminary evidence for the capacity of psychedelic substances for treating addiction, depression, anxiety, and eating disorders (29–35).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [31]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Research works printed but not linked: 16
- Furst P., 1994, Alucinógenos y cultura
- Grob C., 1998, Heffter Rev Psychedelic Res, 1, 8
- Grof S., 2001, LSD psychotherapy
- Halpern J., 2008, Med Sci Monit, 14, SR15
- Harner M., 1976, Alucinógenos y chamanismo
- Hintzen A., 2010, The pharmacology of lysergic acid diethylamide: a critical review
- Hofmann A., 2005, LSD: my problem child
- House R., 1997, NIDA Res Monogr, 173, 175
- Labate B., 2009, Ayahuasca religions: a comprehensive bibliography and critical essays
- Lima L., 2006, Ärztez Naturheilverfahren, 47, 476
- Ott J., 1994, Ayahuasca analogues: pangaean entheogens
- Ott J., 2004, Pharmacotheon: drogas enteogénicas, sus fuentes vegetales y su historia
- Réus G., 2012, Depress Res Treat, 2012, 987397
- Schultes R., 1986, Am Indig, 46, 9
- Schultes R., 1998, Heffter Rev Psychedel Res, 1, 1
- Sos P., 2013, Neuro Endocrinol Lett, 34, 287
Cited by
Items 101–200 of 307
Mason, N. L., & Kuypers, K. P. C. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.006 · Cited by 34
Winne, J., Ciralli, B., Malfatti, T., Brisa, E., Doerl, J. G., Nogueira, I., Leão, K. E., & Leão, R. N. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113175 · Cited by 28
“Recent studies evinced the potential of hallucinogens in treating mood disorders (Davis et al., 2019; Dos Santos et al., 2016; PalhanoFontes et al., 2019; Reiche et al., 2018).”
BackgroundPeacock, C., Mascaro, J. S., Brauer, E., Zarrabi, A. J., Dunlop, B. W., Maples‐Keller, J. L., Grant, G. H., Raison, C. L., Rab, F., & Palitsky, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296071 · Cited by 33
“Psychedelic assisted therapy (PAT) is an experimental treatment with evidence of effectiveness for a range of difficult-to-treat conditions [1] including treatment-resistant depression [2, 3], posttraumatic stress disorder (PTSD) [4], and substance use disorders [5, 6].”
BackgroundMosaffa, S., Ahmadi, H., Khakpai, F., Ebrahimi-Ghiri, M., & Zarrindast, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05679-6 · Cited by 32
Urrutia, J., Anderson, B. T., Belouin, S. J., Berger, A. M., Griffiths, R. R., Grob, C. S., Henningfield, J. E., Labate, B. C., Maier, L. J., Maternowska, M. C., et al. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2258367 · Cited by 31
“…other promising indications (Reiff et al. 2020; Andersen et al. 2021; Köck et al. 2021; Anderson et al. 2020; Ede, Bokor, and Winkelman 2016; dos; Santos et al. 2016; Rodrigues et al. 2022; Palhano-Fontes et al. 2020; De Araújo et al. 2021; Muttoni, Ardissino, and John 2019; Siegel et al. 2021;…”
BackgroundBahji, A., Lunsky, I. O., Gutiérrez, G., & Vázquez, G. H. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2278586 · Cited by 34
Beyond serotonin: newer antidepressants in the future
Rakesh, G., Pae, C., & Masand, P. S. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341310 · Cited by 29
“therapeutic potential with recreational abuse potential [151,152].”
BackgroundSex differences in ketamine's therapeutic effects for mood disorders: A systematic review
Benitah, K. C., Siegel, A. N., Lipsitz, O., Rodrigues, N. B., Meshkat, S., Lee, Y. L., Mansur, R. B., Nasri, F., Lui, L. M. W., McIntyre, R. S., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114579 · Cited by 25
Ayahuasca blocks ethanol preference in an animal model of dependence and shows no acute toxicity
Gianfratti, B., Tabach, R., Sakalem, M. E., Stessuk, T., Maia, L. O., & Carlini, E. A. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114865 · Cited by 31
Isham, A., Elf, P., & Jackson, T. P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1051478 · Cited by 27
Wießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., Ribeiro, S. T. G., Mota, N. B., de Araújo, D. B., & Tófoli, L. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-06006-3 · Cited by 24
Kolasa, M., Nikiforuk, A., Korlatowicz, A., Solich, J., Potasiewicz, A., Dziedzicka‐Wasylewska, M., Bugno, R., Hogendorf, A. S., Bojarski, A. J., & Faron‐Górecka, A. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06644-3 · Cited by 29
New and Emerging Opioid Overdose Risk Factors
Foglia, R., Kline, A., & Cooperman, N. A. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00368-6 · Cited by 27
Amazonian Medicine and the Psychedelic Revival: Considering the “Dieta”
O’Shaughnessy, D. M., & Berlowitz, I. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.639124 · Cited by 37
“As a point of comparison, although tobacco has a dominant place in Amazonian medicine (and shamanic healing beyond South America; Kroeber, 1941), there is a paucity of clinical research on it (Berlowitz et al., 2020), which is quite striking when contrasted with the body of existing work on ayahuasca (Dos Santos et al…”
BackgroundResultInfluentialSubstances of abuse and the blood brain barrier: Interactions with physical exercise
Małkiewicz, M. A., Małecki, A., Toborek, M. J., Szarmach, A., & Winklewski, P. J. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.026 · Cited by 23
Glavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 24
“Ayahuasca has the ability to alter one's state of consciousness, allowing subjects to feel more relaxed and introspective (Barbosa et al., 2005) and has shown great potential for the treatment of anxiety and depression (Dominguez- Clave et al., 2016; Dos Santos et al., 2016).”
BackgroundThe philosophy of psychedelic transformation
Letheby, C. (2017) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.4225/55/5900324d2ad60 · Cited by 18
“One of the most interesting lines of research in the psychedelic renaissance has been the use of modern neuroimaging technologies to probe neural correlates of psychedelic consciousness alteration in humans (reviewed in dos Santos et al. 2016b).”
BackgroundAyahuasca and the traveller: A scoping review of risks and possible benefits
Houle, S. K. D., Evans, D., Carter, C. A., & Schlagenhauf, P. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102206 · Cited by 20
The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies
Low, Z. X. B., Ng, W. S., Lim, E. S. Y., Goh, B. H., & Kumari, Y. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111139 · Cited by 27
Gao, C., Kong, S., Guo, B., Liang, X., Duan, H.-F., & Li, D. (2019) · Medical Science Monitor · doi:10.12659/msm.912922 · Cited by 20
“Depression is a prevalent disorder that is often chronic, and which is associated with psycho-social and physical problems, as well as suicide [1].”
BackgroundGermann, C. B. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109406 · Cited by 22
Being for no-one: Psychedelic experience and minimal subjectivity
Letheby, C. (2020) · Philosophy and the Mind Sciences · doi:10.33735/phimisci.2020.i.47 · Cited by 20
“Indeed, despite the longstanding conception of psychedelics as “psychotomimetic” (psychosis-mimicking) drugs (Sessa, 2012), a growing body of evidence suggests that psychedelic experiences are associated with improved mental health outcomes (Johansen & Krebs, 2015), especially in controlled conditions (Santos et al.,…”
BackgroundCardiovascular effects and safety of classic psychedelics
Nahlawi, A., Ptaszek, L. M., & Ruskin, J. N. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00608-2 · Cited by 25
Perna, J., Trop, J., Palitsky, R., Bosshardt, Z., Vantine, H., Dunlop, B. W., & Zarrabi, A. J. (2025) · BMC Psychiatry · doi:10.1186/s12888-024-06303-z · Cited by 25
Reaction of N , N -Dimethyltryptamine with Dichloromethane Under Common Experimental Conditions
Dunlap, L. E., & Olson, D. E. (2018) · ACS Omega · doi:10.1021/acsomega.8b00507 · Cited by 19
Lysergic acid diethylamide induces increased signalling entropy in rats’ prefrontal cortex
Savino, A., & Nichols, C. D. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15534 · Cited by 22
Perkins, D., Opaleye, E. S., Bouso, J. C., Tófoli, L. F., Sarris, J. J., Schubert, V., Ruffell, S., & Šimonová, H. (2023) · Psychoactives · doi:10.3390/psychoactives2040017 · Cited by 22
“…of note include increased neurogenesis and neuroplasticity [21,23]; modulation of brain network connectivity [24]; serotonergic, MAOI and anti-inflammatory effects [25]; and modulation of the amygdala and right insula, as well brain areas involved in emotional processing and interoception [26–29].”
Naturalizing psychedelic spirituality
Letheby, C. (2017) · Zygon: Journal of Religion and Science · doi:10.1111/zygo.12353 · Cited by 18
“Besides these, small studies have also investigated the potential of psilo-cybin, LSD, and ayahuasca to treat addiction, obsessive-compulsive disorder, and depression, with uniformly promising albeit tentative results (reviewed in dos Santos et al. 2016a).”
BackgroundNewton, K., & Moreton, S. G. (2022) · Ecopsychology · doi:10.1089/eco.2022.0044 · Cited by 22
“mong the emerging research into the therapeutic benefits of psychedelics (Dos Santos et al., 2016), there has been an increasing focus on the positive psychological outcomes of psychedelics in non-clinical populations (Gandy, 2019). body of work has highlighted the capacity for psyche-delics to…”
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Estric, C., Duron, T., Kabani, S., & López‐Castromán, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338214 · Cited by 19
“Yet there is considerable heterogeneity in the set and setting parameters in clinical trials (dos Santos et al., 2016; Wheeler and Dyer, 2020).”
Alves, C. L., Cury, R. G., Roster, K. I. O., Pineda, A. M., Rodrigues, F. A., Thielemann, C., & Ciba, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277257 · Cited by 18
“Additionally, ayahuasca has been shown to elicit anti-neuroinflammatory properties [16] and stimulate adult neurogenesis in vitro [17].”
Walther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 22
Calder, A. E., Hase, A., & Hasler, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02830-z · Cited by 25
Kübel, S. L., Fiedler, H., & Wittmann, M. (2020) · PsyCh Journal · doi:10.1002/pchj.395 · Cited by 22
Therapeutic Potential Ascribed to Ayahuasca by Users in the Czech Republic
Horák, M., Hasíková, L., & Verter, N. (2018) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2018.1511878 · Cited by 17
“Neuropsychological studies have not confirmed any occurrence of cognitive deficits in long-term ayahuasca users (Bouso et al. 2013; dos Santos et al. 2016a; Ribeiro Barbosa et al. 2012, 2016).”
BackgroundResultArgento, E., Tupper, K. W., & Socias, M. E. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2018.11.006 · Cited by 20
Natural Psychoplastogens As Antidepressant Agents
Benko, J., & Vranková, S. (2020) · Molecules · doi:10.3390/molecules25051172 · Cited by 19
Vorobyeva, N. S., & Kozlova, A. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927984 · Cited by 24
Ayahuasca: what mental health professionals need to know
SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2017) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000130 · Cited by 25
Self-citationvan Oorsouw, K. I. M., Uthaug, M. V., Mason, N. L., Broers, N. J., & Ramaekers, J. G. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00174 · Cited by 20
Marchi, M., Farina, R., Rachedi, K., Laonigro, F., Žuljević, M. F., Pingani, L., Ferrari, S., Somers, M., Boks, M. P., & Galeazzi, G. M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303594 · Cited by 23
“The comparable efficacy of psilocybin and LSD could have been expected, as their mechanism of action and subjective effects are closely comparable (dos Santos et al., 2016; Ley et al., 2023).”
Fungal-Derived Natural Product: Synthesis, Function, and Applications
Singh, A. K., Rana, H. K., & Pandey, A. K. (2019) · Fungal biology · doi:10.1007/978-3-030-14846-1_8 · Cited by 16
Madrid-Gambín, F., Gomez‐Gómez, À., Busquets-García, A., Haro, N., Marco, S., Mason, N. L., Reckweg, J. T., Mallaroni, P., Kloft, L., van Oorsouw, K. I. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112845 · Cited by 18
Askariyan, K., Joghataei, M. T., Dehghan, S., Nohesara, S., Rihipour, L., Mohammadi, M. H., & Ahmadirad, N. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111461 · Cited by 15
Key Characteristics and Development of Psychoceuticals: A Review
Cano, G. E. H., Dean, J., Abreu, S. P., Rodríguez, A. H., Abbasi, C., Hinson, M., & Lucke-Wold, B. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415777 · Cited by 15
Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness
Mograbi, D. C., Rodrigues, R. F. S., Bienemann, B., & Huntley, J. D. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01353-y · Cited by 22
Lessons to be learned from early psychedelic therapy in Denmark
Erritzoe, D., & Richards, W. A. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1336252 · Cited by 14
“Notably, no significant adverse events, hereunder occurrence of flashbacks, flashbacks have been reported, and the results have overall been positive across these conditions that have been investigated (10,11).”
BackgroundAixalà, M., SANTOS, R. G. D., Hallak, J. E. C., & Bouso, J. C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00237 · Cited by 21
Self-citationRossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Oña, G., Silveira, G. D. O., Yonamine, M., Bertozi, G., Crevelin, E. J., Queiroz, M. E. C., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001691 · Cited by 13
Self-citationKoning, E., & Brietzke, E. M. (2024) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2022-0597 · Cited by 22
“21,36,50 In humans, multiple small-scale studies have demonstrated statistically significant effects of psilocybin on OCD-related symptom reduction, linked to its actions on serotonergic signaling and cerebral connectivity.”
InfluentialPresent and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Madrid-Gambín, F., Fabregat‐Safont, D., Gomez‐Gómez, À., Olesti, E., Mason, N. L., Ramaekers, J. G., & Pozo, Ó. J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115775 · Cited by 16
Bodnár, J. K., & Kakuk, P. (2018) · Medicine Health Care and Philosophy · doi:10.1007/s11019-018-9871-9 · Cited by 13
Primum non nocere: The onus to characterize the potential harms of psychedelic treatment
Ghaznavi, S., Ruskin, J. N., Haggerty, S. J., King, F., & Rosenbaum, J. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230914 · Cited by 12
Skeletal editing by iron-catalyzed carbene insertion of trichloromethanes
DeMuynck, B. M., Hyland, E. E., Kim, H., Menches, V., Vernier, A. M. M., Wang, Z., Olson, D. E., Levin, M. D., & Nagib, D. A. (2026) · Chem · doi:10.1016/j.chempr.2026.102968 · Cited by 16
Schedule 1 barriers to research in the UK: An in-depth qualitative analysis
Howard, A., Neill, J. C., Schlag, A. K., & Lennox, C. (2021) · Drug Science Policy and Law · doi:10.1177/20503245211049313 · Cited by 15
“These findings provide support for the psychology of working theory (PWT; Duffy et al., 2016), which maintains that contextual and structural factors, such as economic constraints, work volition and marginalisation predict decent work; this relationship is proposed to be moderated by several other…”
BackgroundKrupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 13
“…al., 2018; Yaeger et al., 2020, 2022a, 2022b) and psychedelics (Carhart-Harris et al., 2018; Carhart-Harris et al., 2021; De Gregorio et al., 2021; dos Santos et al., 2016; Griffiths et al., 2016; Johnson and Griffiths, 2017; Kyzar et al., 2017; Nichols et al., 2017b; Nichols, 2016; Ross et al.,…”
BackgroundNižňanský, Ľ., Nižnanská, Ž., Kuruc, R., Szórádová, A., Šikuta, J., & Zummerová, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041147 · Cited by 16
“It is well known that ayahuasca may have antidepressant effects (reviewed in [82]) and also that the development of manic episodes in psychiatric patients after the administration of antidepressants is a criterion for the diagnosis of bipolar disorder [81].”
BackgroundMicrodosing psychedelics as cognitive and emotional enhancers.
Rifkin, B. D., Maraver, M. J., & Colzato, L. S. (2020) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000213 · Cited by 16
Kubicskó, K., & Farkas, Ö. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01118e · Cited by 12
Exploring the effect of microdosing psychedelics on creativity in an open-label natural settingPreprint
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchař, M., Sjoerds, Z., & Hommel, B. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/384412 · Cited by 12
Mardal, M., Johansen, S. S., Thomsen, R., & Línnet, K. (2017) · Forensic Science International · doi:10.1016/j.forsciint.2017.07.025 · Cited by 11
Guenzel, N., & McChargue, D. E. (2019) · StatPearls · Cited by 19
Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice
Denis-Lalonde, D., & Estefan, A. (2020) · Journal of Mental Health and Addiction Nursing · doi:10.22374/jmhan.v4i1.40 · Cited by 15
“Psilocybin and Depression Psilocybin is a psychoactive compound that, while found in over 100 species of mushrooms, can also be synthesized.(21,31) Preliminary evidence suggests that psilocybin may be a better option to currently available therapies for depression and has accordingly been granted Breakthrough Therapy…”
BackgroundAyahuasca: Between Cognition and Culture
Peláez, I. E. A. (2020) · Publicacions URV eBooks · doi:10.17345/9788484248347 · Cited by 11
van der Gronde, T., Los, L., Herremans, A. H. J., Oosting, R. S., Zorzanelli, R., & Pieters, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00412 · Cited by 13
“A brief overview of the indications these psychedelics have been investigated for post-2000 is indicated in Table 1 (69, 70, 72).”
BackgroundInfluentialAyahuasca in the Czech Republic: Extended Version
Horák, M., & Verter, N. (2019) · doi:10.11118/978-80-7509-657-9 · Cited by 12
Classic psychedelics and the treatment for alcoholism
Lodetti, G., de Bitencourt, R. M., & Rico, E. P. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111129 · Cited by 17
Bottemanne, H., Claret, A., & Fossati, P. (2020) · L Encéphale · doi:10.1016/j.encep.2020.08.006 · Cited by 15
Turkia, M. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/t6k9b · Cited by 17
Ford, S. A., Ness, R. W., Kwon, M., Ro, D., & Phillips, M. A. (2024) · BMC Plant Biology · doi:10.1186/s12870-024-05633-0 · Cited by 10
Berlowitz, I., Pesantes, M. A., Palacios, C. C., Martin-Söelch, C., Wolf, U., & Maake, C. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003912 · Cited by 15
Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder
Hornick, M. G., & Stefanski, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1221719 · Cited by 10
Tuck, J. R., Dunlap, L. E., & Olson, D. E. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c01363 · Cited by 9
Smith, F. N., Neill, J. C., & Wainwright, V. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221124117 · Cited by 13
A role for enhanced functions of sleep in psychedelic therapy?
Froese, T., Leenen, I., & Páleníček, T. (2018) · Adaptive Behavior · doi:10.1177/1059712318762735 · Cited by 8
“…in well-being and mood in healthy subjects and in patients suffering from severe depression and anxiety, attenuation of addictions, and reduction in unwanted behavioral patterns (for reviews, see CarhartHarris & Goodwin, 2017; Dos Santos et al., 2016; Garcia-Romeu, Kersgaard, & Addy, 2016).”
BackgroundA Descriptive Analysis of Body Composition Among Forest Firefighters in Spain
Crespo-Ruiz, B., García, P. E., Fernández-Vega, C., Crespo-Ruiz, C., & Rivas-Galan, S. (2020) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000001842 · Cited by 8
Psychothérapie augmentée par la kétamine (KAP) dans les troubles de l’humeur : mode d’emploi
Bottemanne, H., Baldacci, A., Muller, C., Boyreau, A., & Claret, A. (2021) · L Encéphale · doi:10.1016/j.encep.2021.08.011 · Cited by 13
Turkia, M. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100029 · Cited by 18
The influence of context on ayahuasca experiences: An analysis of experience reports
Sapoznikow, A., Walsh, Z., Tupper, K. W., Erowid, E., & Erowid, F. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.028 · Cited by 10
Can Psychedelics be the Treatment for the Crisis in Psychopharmacology?Preprint
Oña, G., & Bouso, J. C. (2019) · Preprints.org · doi:10.20944/preprints201901.0249.v1 · Cited by 8
“…the first evidence-based and pharmacologically-mediated cure in psychiatry.63 For a review of the clinical use of psychedelic drugs, see dos Santos et al. 2016.64 In addition to these substances, it is also remarkable the therapeutic potential that ibogaine has shown for the treatment of…”
BackgroundInfluentialMapping Psilocybin-Assisted Therapies: A Scoping ReviewPreprint
Shore, R., Ioudovski, P., Goldie, C. E., McKeown, S., & Dumont, É. C. (2019) · medRxiv · doi:10.1101/2019.12.04.19013896 · Cited by 10
Gomonit, M. M., Skillman, B. N., & Swortwood, M. J. (2023) · Journal of Forensic Sciences · doi:10.1111/1556-4029.15454 · Cited by 9
Bassi, M., Bilel, S., Tirri, M., Corli, G., Rosa, F. D., Gregori, A., Alkilany, A. M., Rachid, O., Roda, E., Zauli, G., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06526-8 · Cited by 9
“…a revival of interest in psychedelics in this area and several studies and clinical trials have suggested their effectiveness in the treatment of alcohol dependence, anxiety, and major depression disorder (Bogenschutz et al. 2015; Dos Santos et al. 2016; Davis et al. 2021; De Gregorio et al. 2021).”
BackgroundSANTOS, R. G. D., Osório, F. D. L., Crippa, J. A. S., & Hallak, J. E. C. (2017) · Journal of Psychedelic Studies · doi:10.1556/2054.01.2017.004 · Cited by 10
Self-citationMonoaminergic system and antidepressants
Martín‐Hernández, D., Ulecia-Morón, C., Bris, Á. G., Pereira, M. P., & Caso, J. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00093-1 · Cited by 10
Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets
de Sousa, T. R., Rema, J., Machado, S. E. D. C., & Novais, F. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211201145800 · Cited by 8
Taraxacum officinale: The Esculent Dandelion as Herbal Medicine
Qadir, I., Nazir, S., Sheikh, M. A., Naaz, F., Bashir, S., Ovais, S., Khan, N. A., & Masoodi, M. H. (2022) · Springer eBooks · doi:10.1007/978-981-16-4959-2_9 · Cited by 7
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample
Jones, G. M., Ricard, J. A., Hendricks, P. S., & Simonsson, O. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127318 · Cited by 10
“Although these investigations did not examine ecstasy, there are overlapping psychological mechanisms between ecstasy and classic psychedelics (Dos Santos et al., 2016; Mithoefer et al., 2016) and thus ecstasy may also induce similar positive changes to health behaviors.”
BackgroundThe Misclassification of Medical Marijuana.
Krystal, H. L. (2018) · PubMed · doi:10.29158/jaapl.003790-18 · Cited by 8
“Cannabis is not the only drug on this list to have potential medical use; LSD, for example, has recently been considered for use as an antidepressant or anxiolytic.(12)”
BackgroundMeyer, T. D., Ibrahim, M., Vale, L., & Soares, J. C. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.044 · Cited by 7
Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism
Bonniwell, E. M., Alabdali, R., Hennessey, J. J., McKee, J. L., Cavalco, N. G., Lammers, J. C., Moore, E. J., Franchini, L., Orlandi, C., & McCorvy, J. D. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00647 · Cited by 9
Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?
Postránecká, Z., Vejmola, Č., & Tylš, F. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.003 · Cited by 8
“The results available to date clearly indicate that certain patients could benefit from psychedelics as a fast-acting treatment option with long-term effect and minimal adverse effects (Santos et al., 2016).”
BackgroundAyahuasca as a Healing Tool Along the Continuum of Recovery from Eating Disorders
Lafrance, A., Renelli, M., Fletcher, J., Files, N., Tupper, K. W., & Loizaga-Velder, A. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_11 · Cited by 8
Márquez, B. D. P., & Dietl, B. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.02.017 · Cited by 6
Treatment resistant depression
Vaccarino, S. R., & Kennedy, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00003-4 · Cited by 8
Argento, E., Capler, R., THOMAS, G. W., Lucas, P., & Tupper, K. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_10 · Cited by 6
Horák, M. (2017) · Mendelova univerzita v Brně eBooks · doi:10.11118/978-80-7509-510-7 · Cited by 6
Conn, K., Milton, L. K., Huang, K., Munguba, H., Ruuska, J., Lemus, M. B., Greaves, E., Homman‐Ludiye, J., Oldfield, B. J., & Foldi, C. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.12.571374 · Cited by 6
“Unfortunately, efforts in this space have focused largely on traditional assays of depression-related behaviour in rodents 31 , with variable findings of either improvements 32 or no effects 33 , dependent on the assay or animal model used 34 .”
MethodScuro, J. (2024) · Social Compass · doi:10.1177/00377686241301923 · Cited by 6
“Ayahuasca also has promising therapeutic research (Breeksema et al., 2020; Dos Santos et al., 2016), although progress lags behind psilocybin.”
Impact of psychedelics on craving in addiction: A systematic review
Chapron, S., Bonazzi, G., Lodovico, L. D., de Ternay, J., Landmann, C., Nourredine, M., Salvo, F., Sessa, B., Das, R., Rolland, B., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241308613 · Cited by 7
“Consequently, there is a strong need for new medications in this field, a role some have suggested psych-edelics could fill (Bogenschutz and Johnson, 2016; DiVito and Leger, 2020; Dos Santos et al., 2016; Jones et al., 2018; Sessa, 2018; Winkelman, 2014).”
Metadata
- Authors
- dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C.
- Affiliations
- Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, Brazil
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, SP, Brazil National Institute for Translational Medicine (INCT-TM), CNPq, Brazil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-03-18
- Volume
- 6
- Issue
- 3
- Pages
- 193-213
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC4910400
- OpenAlex
- W2325558246
- Cited by
- 306
- References
- 196
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 50 · 2023: 28 · 2022: 32 · 2021: 44 · 2020: 35 · 2019: 27 · 2018: 29 · 2017: 20 · 2016: 5
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- ayahuasca, psilocybin, lysergic acid diethylamide, antidepressant effects, anxiolytic effects, treatment-resistant depression, anxiety disorders, drug addiction, tobacco dependence, alcoholism, psychedelics, mood disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.